Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-03-29 5:24 pm Unchanged |
2023-03-27 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 7,619,135 13.400% |
0 (Unchanged) |
Filing History |
| 2023-03-24 4:57 pm Purchase |
2023-03-22 | 13D | CalciMedica, Inc. CALC |
ORBIMED ADVISORS LLC | 297,380 5.400% |
297,380 (New Position) |
Filing History |
| 2023-03-24 4:43 pm Sale |
2023-03-22 | 13D | 89bio, Inc. ETNB |
ORBIMED ADVISORS LLC | 0 0.000% |
-1,504,436 (Position Closed) |
Filing History |
| 2023-03-22 4:27 pm Purchase |
2023-03-20 | 13D | CalciMedica, Inc. CALC |
ORBIMED ADVISORS LLC | 297,380 18.900% |
297,380 (New Position) |
Filing History |
| 2023-03-14 4:19 pm Purchase |
2023-03-09 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 17,233,668 39.600% |
395,000 (+2.35%) |
Filing History |
| 2023-02-28 5:09 pm Sale |
2023-02-16 | 13D | Fusion Pharmaceuticals Inc. FUSN |
ORBIMED ADVISORS LLC | 2,930,670 4.700% |
-67,311 (-2.25%) |
Filing History |
| 2023-02-28 4:00 pm Purchase |
2023-02-23 | 13D | Enliven Therapeutics, Inc. ELVN |
ORBIMED ADVISORS LLC | 8,949,339 21.800% |
8,949,339 (New Position) |
Filing History |
| 2023-02-23 3:23 pm Purchase |
2023-02-17 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 4,693,629 10.600% |
1,295,700 (+38.13%) |
Filing History |
| 2023-02-14 5:24 pm Purchase |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 344,288 8.200% |
283,077 (+462.46%) |
Filing History |
| 2023-02-14 5:20 pm Sale |
2022-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN |
ORBIMED ADVISORS LLC | 0 0.000% |
-350,641 (Position Closed) |
Filing History |
| 2023-02-14 5:16 pm Purchase |
2022-12-31 | 13G | Verastem, Inc. VSTM |
ORBIMED ADVISORS LLC | 1,375,270 7.900% |
1,375,270 (New Position) |
Filing History |
| 2023-02-14 5:12 pm Purchase |
2022-12-31 | 13G | VectivBio Holding AG VECT |
ORBIMED ADVISORS LLC | 6,713,561 10.700% |
1,810,057 (+36.91%) |
Filing History |
| 2023-02-14 5:07 pm Sale |
2022-12-31 | 13G | Theravance Biopharma, Inc. TBPH |
ORBIMED ADVISORS LLC | 0 0.000% |
-5,456,780 (Position Closed) |
Filing History |
| 2023-02-14 5:04 pm Sale |
2022-12-31 | 13G | Sonendo, Inc. SONX |
ORBIMED ADVISORS LLC | 0 0.000% |
-49 (Position Closed) |
Filing History |
| 2023-02-14 4:59 pm Purchase |
2022-12-31 | 13G | SI-BONE, Inc. SIBN |
ORBIMED ADVISORS LLC | 3,201,100 9.300% |
3,201,100 (New Position) |
Filing History |
| 2023-02-14 4:55 pm Sale |
2022-12-31 | 13G | RxSight, Inc. RXST |
ORBIMED ADVISORS LLC | 923,733 3.300% |
-138,767 (-13.06%) |
Filing History |
| 2023-02-14 4:52 pm Unchanged |
2022-12-31 | 13G | Protara Therapeutics, Inc. TARA |
ORBIMED ADVISORS LLC | 671,741 6.000% |
0 (Unchanged) |
Filing History |
| 2023-02-14 4:48 pm Unchanged |
2022-12-31 | 13G | NeuroPace, Inc. NPCE |
ORBIMED ADVISORS LLC | 4,012,281 16.100% |
0 (Unchanged) |
Filing History |
| 2023-02-14 4:43 pm Purchase |
2022-12-31 | 13G | Mersana Therapeutics, Inc. MRSN |
ORBIMED ADVISORS LLC | 7,082,837 7.100% |
7,082,837 (New Position) |
Filing History |
| 2023-02-14 4:40 pm Purchase |
2022-12-31 | 13G | Mereo BioPharma Group plc MREO |
ORBIMED ADVISORS LLC | 10,378,591 5.920% |
4,315,246 (+71.17%) |
Filing History |